Roche and Genentech Unveil Cutting-Edge R&D Hub at Harvard Campus to Revolutionize Healthcare Research

Roche and Genentech Unveil Cutting-Edge R&D Hub at Harvard Campus to Revolutionize Healthcare Research

(IN BRIEF) Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a hub that will drive breakthroughs in Cardiovascular, Renal, and Metabolism research while also leveraging data science and AI to accelerate drug development. Starting with a 30,000-square-foot lease and the potential to expand to a facility housing up to 500 employees, the center exemplifies Roche’s long-standing collaboration with Harvard and reinforces its commitment to investing in the Boston healthcare ecosystem. Local leaders and company executives highlighted the center’s role in fostering innovation, creating jobs, and strengthening public-private partnerships in the life sciences sector.

(PRESS RELEASE) BASEL, 7-Mar-2025 — /EuropaWire/ — Roche has unveiled the new Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, signaling a major step forward in its commitment to innovation within the healthcare sector. Serving as a dual hub for both Roche and Genentech, the center will focus on advancing research in Cardiovascular, Renal, and Metabolism areas while also harnessing data science and AI to speed up drug discovery and development. Initially occupying a 30,000-square-foot space, the facility is planned to expand over time, potentially hosting up to 500 employees under the guidance of Manu Chakravarthy, SVP and Global Head of CVRM Product Development.

This new center further cements the longstanding collaboration between Roche and Harvard, enhancing their influence in the vibrant Boston healthcare ecosystem. Roche CEO Thomas Schinecker emphasized that leveraging the region’s rich pool of talent will help propel research initiatives and drive the company’s US investments, which have exceeded USD11 billion over the past decade. The announcement has been warmly received by local leaders; Harvard University President Alan Garber, Massachusetts Governor Maura Healey, and Boston Mayor Michelle Wu all highlighted the center’s potential to create jobs, foster innovation, and strengthen public-private partnerships in the life sciences field.

The center is part of Harvard’s Enterprise Research Campus, a dynamic mixed-use development designed to promote innovation and collaboration by integrating cutting-edge laboratory space with community-focused amenities.

About the Enterprise Research Campus
Harvard’s Enterprise Research Campus, the first phase of which is underway and developed by Tishman Speyer and Breakthrough Properties, has been intentionally designed to foster innovation and collaboration. Located adjacent to Harvard’s Science and Engineering Complex and near Harvard Business School, the ERC will be a dynamic mixed-use development integrating research and laboratory space, residential buildings, a hotel, conference center, retail units, and a variety of community-centered outdoor spaces. The first phase of construction is expected to be complete in 2026.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Media Contacts:

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com